Lupin has announced plans to carve out its trade generics business in India to its Lupin Life Sciences Limited subsidiary, as part of efforts to achieve “agility, better focus and growth” for the unit.
Lupin has become the latest Indian player to shine a spotlight on its domestic trade generics business, announcing plans to carve out the unit “as a going concern, on a slump sale basis, to Lupin Life Sciences Limited, a wholly owned subsidiary of the company.”
The Indian trade generics business – which achieved sales of around INR2.78bn ($33m) in Lupin’s most recent financial year, representing...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
